null

VivoGenie Anti-Human RANKL (Denosumab) Biosimilar (IVMB0490)

SKU:
IVMB0490
Antibody Type:
In Vivo Biosimilar
Endotoxin Level:
Low Endotoxin
Applications:
In Vivo
Disease Area:
Cancer
$407 - $13,535

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human RANKL (Denosumab)
SKU:IVMB0490
Size:1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:AMG-162
Target:RANKL
Isotype:Human IgG2κ
Host Species:Human
Reactivity:Human
Applications:ELISA
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:osteoprotegerin ligand (OPGL), osteoclast differentiation factor (ODF), TNF related activation-induced cytokine (TRANCE), tumor necrosis factor ligand superfamily member 11 (TNFSF11)
Product Concentration:≥ 5.0 mg/ml
Purity:≥95% by SDS Page
Immunogen:Purified Recombinant Human RANKL
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Antigen Distribution:RANKL binds to its receptor RANK, which is located on osteoclasts and osteoclast precursors.
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Specificity:Denosumab activity is directed against human RANKL (receptor activator of NFκB ligand).
Additional Applications Reported In Literature:ELISA WB IHC FA
Recommended Isotype Controls:Human IgG2

Osteoporosis is a disease of bone microarchitecture deterioration commonly seen in postmenopausal women1. Estrogen deficiency leads to low bone mass and increased bone fragility due to bone resorption increasing more than formation. Those affected have an increased risk of fracture. RANKL (receptor activator of NFκB ligand) is a TNF family member that acts as a key bone resorption protein by mediating osteoclast formation, activation, and survival via activating its receptor RANK1,2.

Denosumab, a fully human monoclonal antibody originally generated using transgenic Xenomouse technology, selectively and with high affinity binds to and inhibits human RANKL, thus preventing interaction with and activation of its receptor RANK on the surface of osteoclasts and their precursors2. This blocking activity inhibits the formation, function, and survival of osteoclasts, resulting in reduced bone resorption and consequently reduces the risk of vertebral, nonvertebral and hip fractures. Denosumab increases bone mineral density (BMD) and trabecular and cortical bone strength, with continued antifracture and BMD benefits over 10 years of therapy. Bone resorption is inhibited in cynomolgus monkeys and humans, but not normal mice or rats.

Unlike bisphosphonates, denosumab is not incorporated into bone and its effects on bone turnover markers, BMD and histomorphometric measures are generally reversed upon its discontinuation1.

Ligand/Receptor:RANK/RANKL
State of Matter:Liquid
Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Product Preparation:Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
UniProt:O14788
Research Area:Biosimilars

Related Products